Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3A | P31941 | 2/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29476719 | 0.91 | APOBEC3A (0.44) | APOBEC3AAPOBEC3GL3MBTL1RAB9AKDM4E | |
| SCHEMBL869513 | 0.91 | APOBEC3A (0.44) | APOBEC3AAPOBEC3GL3MBTL1RAB9AKDM4E | |
| SCHEMBL29476546 | 0.88 | L3MBTL1 (0.53) | APOBEC3AAPOBEC3GL3MBTL1RAB9AKDM4E | |
| SCHEMBL870743 | 0.87 | RAB9A (0.40) | APOBEC3AAPOBEC3GL3MBTL1RAB9AKDM4E | |
| SCHEMBL29476634 | 0.87 | RAB9A (0.40) | APOBEC3AAPOBEC3GL3MBTL1RAB9AKDM4E | |
| SCHEMBL870111 | 0.83 | L3MBTL1 (0.50) | APOBEC3AAPOBEC3GL3MBTL1RAB9AKDM4E | |
| SCHEMBL869701 | 0.83 | APOBEC3A (0.44) | APOBEC3AAPOBEC3GL3MBTL1RAB9AKDM4E | |
| SCHEMBL29476693 | 0.83 | APOBEC3A (0.44) | APOBEC3AAPOBEC3GL3MBTL1RAB9AKDM4E | |
| SCHEMBL29476660 | 0.82 | APOBEC3A (0.47) | APOBEC3AAPOBEC3GL3MBTL1RAB9AKDM4E | |
| SCHEMBL870742 | 0.82 | APOBEC3A (0.47) | APOBEC3AAPOBEC3GL3MBTL1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360156-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-10-31 | — | — | US | disclosed |
| US-11279713-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360156-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | APOBEC3A 2706/4885APOBEC3G 2810/4885L3MBTL1 4639/4885 |
| US-11279713-B2 | Heterocyclic compound and use thereof | GRIN1, GRIN2C, GRIN2A | APOBEC3A 2706/4885APOBEC3G 2810/4885L3MBTL1 4639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.